WeVote
Log In

Bill

Bill

H 4956

An Act relating to patient choice in dispensing of clinician-administered drugs

194th Legislature (2025-2026) Introduced by Lindsay Sabadosa

The bill would expand how patients can obtain clinician-administered drugs, increasing dispensing options while maintaining safety and care quality.

Reporting date extended to Thursday, December 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 4956

Summary of H.4956 (Session 194th) — Massachusetts

Title

An Act relating to patient choice in dispensing of clinician-administered drugs

Purpose and intent

  • The bill aims to enhance patient choice by addressing how clinician-administered drugs are dispensed. It seeks to clarify and potentially expand opportunities for patients to obtain certain medications directly through dispensing arrangements, with an emphasis on patient autonomy and access to care.
  • By modifying dispensing requirements or processes, the measure targets the interface between clinicians, patients, and pharmacies to streamline or diversify how clinician-administered drugs are provided.

Key provisions and changes (as indicated by available bill history)

  • The bill appears to focus on the dispensing pathway for drugs that clinicians administer directly to patients, potentially allowing for greater flexibility in how these drugs are supplied (e.g., through clinical settings, pharmacies, or other dispensing channels).
  • It may introduce or adjust regulatory or administrative standards governing who may dispense clinician-administered drugs, under what conditions, and with what documentation.
  • The changes are designed to preserve patient safety and care quality while expanding patient choice in how treatment is delivered.

Note: The exact text of provisions is not provided in the summary you supplied. The description reflects the bill’s stated intent and typical mechanisms used in related dispensing-coverage reforms.

Who or what would be affected

  • Patients receiving clinician-administered drugs: Potentially more options and flexibility in obtaining these medications.
  • Clinicians and clinical practices: Possible changes to dispensing workflows, collaboration with pharmacies, or requirements for dispensing under patient-choice provisions.
  • Pharmacies and pharmaceutical distributors: If new dispensing pathways are authorized, these entities could experience changes in stocking, dispensing authority, or reimbursement processes.
  • Payers (public and private): Possible implications for coverage policies, prior authorization, and reimbursement procedures related to clinician-administered drugs.

Procedural and timeline aspects

  • The bill originated with a drafting iteration labeled H1313, suggesting revisions and refinement during the committee process.
  • Action history indicates:
    • January 28, 2026: Reported favorably by the Committee on Financial Services and referred to the Committee on Health Care Financing.
    • January 28, 2026: New draft presented (H1313).
    • July 9, 2026: Reporting date extended to December 31, 2026.
  • Co-sponsor: Lindsay Sabadosa.
  • The legislative path includes committee approvals and potential floor consideration, with an extended reporting deadline indicating delayed timing for further action.

Potential impacts and considerations

  • Benefits may include improved patient satisfaction, reduced time to receipt of therapy, and increased access in rural or underserved areas if dispensing options broaden.
  • Safety, oversight, and regulatory compliance will be central considerations, including accurate administration records, reconciliation of doses, and appropriate reimbursements.
  • Stakeholders may seek clarifications on eligibility, patient eligibility criteria, and the roles of pharmacists, nurse practitioners, physician assistants, and physicians in dispensing.

Summary

H.4956 seeks to advance patient choice in how clinician-administered drugs are dispensed in Massachusetts. By potentially expanding dispensing pathways and clarifying regulatory expectations, the bill aims to balance patient accessibility with safety and quality of care. The proposal is advancing through committees with ongoing deliberation and a scheduled extension for reporting.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.